Opinion

Video

EHA 2024 Highlights: Overcoming Challenges with Bispecific Antibodies in RRMM

Author(s):

Joseph Mikhael, MD

Dr. Mikhael outlines the significant hurdles in bispecific antibody therapy, as presented at the European Hematology Association's 2024 conference.

Video content above is prompted by the following question:

  1. Results from the phase 1/2 MonumenTAL-1 study and phase 1B MonumenTAL-2 study were also presented at EHA 2024. How do the results from these two trials contribute to the evolving role of talquetamab in multiple myeloma?
  2. What is the value of long-term follow-up data in multiple myeloma? How does this impact use of treatment regimens?
  3. What challenges must be considered and overcome with bispecific antibody-containing regimens in RRMM?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
1 expert in this video
1 expert in this video
1 expert in this video
Pieter Sonneveld, MD, PhD
1 expert in this video
1 expert in this video
Pieter Sonneveld, MD, PhD
Ajai Chari, MD
1 expert in this video
1 expert in this video
Related Content
Testing in multiple myeloma | Image credit: angellodeco - stock.adobe.com
June 12th 2025

DVRd Improves MRD Negativity, Maintains Quality of Life in Multiple Myeloma

Pearl Steinzor
Two posters presented at the 2025 European Hematology Association Congress support combination therapy with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) in transplant-ineligible or deferred newly diagnosed multiple myeloma.
Mansi Shah, MD
June 11th 2025

Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

Laura Joszt, MA Hayden E. Klein Mansi Shah, MD
Mansi Shah, MD, discusses the role of stem cell transplant in multiple myeloma (MM) and the logistical barriers to wider adoption of bispecific therapies.
The investigators said real-world use of allo-SCT appeared to be receding as a preferred option after relapse, even before these new data. | Image credit: ibreakstock - stock.adobe.com
June 7th 2025

Auto-SCT Superior to Allo-SCT in Relapsed Myeloma After First-Line Auto-SCT

Jared Kaltwasser
A meta-analysis suggests allogeneic stem cell transplantation (allo-SCT) should not be recommended following first-line autologous stem cell transplant (auto-SCT).
IVBM Phoenix logo | Image: AJMC
May 19th 2025

Translating Best Practices and Ensuring Equitable Care as the Treatment Landscape Evolves

Laura Joszt, MA
AJMC Q&A with Harsh Parmar, MD | Background image credit: ipopba - stock.adobe.com
May 17th 2025

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

Laura Joszt, MA Harsh Parmar, MD
Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com
April 25th 2025

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

Kyle Munz Ajai Chari, MD
When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo